The strange allure of state "right-to-try" laws.
作者信息
Zettler Patricia J, Greely Henry T
机构信息
Center for Law and the Biosciences, Stanford University, Stanford, California.
出版信息
JAMA Intern Med. 2014 Dec;174(12):1885-6. doi: 10.1001/jamainternmed.2014.5767.
Abstract
摘要
相似文献
1
The strange allure of state "right-to-try" laws.
JAMA Intern Med. 2014 Dec;174(12):1885-6. doi: 10.1001/jamainternmed.2014.5767.
2
Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
AMA J Ethics. 2015 Dec 1;17(12):1142-6. doi: 10.1001/journalofethics.2015.17.12.stas1-1512.
3
A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Seton Hall Law Rev. 2009;39(2):559-603.
4
[Off-label use of drugs--the legal framework].
Dtsch Med Wochenschr. 2012 Jul;137(30):1519-23. doi: 10.1055/s-0032-1305172. Epub 2012 Aug 6.
5
Food and Drug Administration responds to pressure for expanded drug access.
J Natl Cancer Inst. 2014 Jun 6;106(6):dju171. doi: 10.1093/jnci/dju171. Print 2014 Jun.
6
Patient advocacy. 'Right to Try' laws bypass FDA for last-ditch treatments.
Science. 2014 Jun 20;344(6190):1329. doi: 10.1126/science.344.6190.1329.
7
The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
JAMA Intern Med. 2018 Mar 1;178(3):321-322. doi: 10.1001/jamainternmed.2017.8167.
8
"Right to Try" Laws: The Gap between Experts and Advocates.
Hastings Cent Rep. 2015 May-Jun;45(3):9-10. doi: 10.1002/hast.442.
9
The Right to Try: An Overview of Efforts to Obtain Expedited Access to Unapproved Treatment for the Terminally Ill.
Food Drug Law J. 2015;70(4):617-41.
10
Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.
JAMA. 2015 Aug 25;314(8):758-60. doi: 10.1001/jama.2015.7691.
引用本文的文献
1
Considerations for applying bioethics norms to a biopharmaceutical industry setting.
BMC Med Ethics. 2021 Mar 25;22(1):31. doi: 10.1186/s12910-021-00600-y.
2
"I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
J Natl Cancer Inst. 2021 Jun 1;113(6):735-741. doi: 10.1093/jnci/djaa137.
3
Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.
Neurology. 2020 Jan 7;94(1):e1-e14. doi: 10.1212/WNL.0000000000008699. Epub 2019 Dec 2.
4
Right to Try Requests and Oncologists' Gatekeeping Obligations.
J Clin Oncol. 2020 Jan 10;38(2):111-114. doi: 10.1200/JCO.19.01741. Epub 2019 Oct 15.
5
The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.
Hastings Cent Rep. 2019 Mar;49(2):36-39. doi: 10.1002/hast.991.
6
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
JACC Basic Transl Sci. 2018 May 30;3(2):280-293. doi: 10.1016/j.jacbts.2017.11.007. eCollection 2018 Apr.
7
Characterizing expanded access and compassionate use programs for experimental drugs.
BMC Res Notes. 2017 Jul 28;10(1):350. doi: 10.1186/s13104-017-2687-5.
8
Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.
J Bioeth Inq. 2017 Sep;14(3):385-400. doi: 10.1007/s11673-017-9791-z. Epub 2017 Jun 20.
9
Overview of FDA's Expanded Access Program for Investigational Drugs.
Ther Innov Regul Sci. 2017 Mar 1;51(2):177-179. doi: 10.1177/2168479017694850.
10
Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
Ther Innov Regul Sci. 2016 Nov;50(6):705-709. doi: 10.1177/2168479016656030.
Zotero 插件